Victory Capital Management
VTGN icon

Victory Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Victory Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-811
Closed -$3.03K – 2615
2023
Q1 		$3.03K Buy
+811
New +$4.25K ﹤0.01% 2581
2021
Q4 		– Sell
-26,524
Closed -$2.18M – 2856
2021
Q3 		$2.18M Buy
26,524
+11,531
+77% +$1M ﹤0.01% 1574
2021
Q2 		$1.42M Buy
14,993
+3,734
+33% +$277K ﹤0.01% 1748
2021
Q1 		$719K Buy
+11,259
New +$752K ﹤0.01% 2048

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management's VTGN Position: Q2 2023 in Review

Victory Capital Management sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 811 shares — an estimated $3.03K sold.

Victory Capital Management first reported a position in VTGN in Q1 2021 and held it in 4 quarters. The position peaked at $2.18M in Q3 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Victory Capital Management reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Victory Capital Management sold 811 VistaGen Therapeutics shares in Q2 2023, an estimated $3.03K.
  • Victory Capital Management first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 4 quarters.
  • Victory Capital Management's VistaGen Therapeutics position peaked at $2.18M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.